Labcorp presents new research demonstrating clinical impact of precision diagnostics in guiding biomarker-targeted therapies for patients with epithelial ovarian cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice burlington, n.c. , march 16, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 sgo annual meeting on women's cancer.
LH Ratings Summary
LH Quant Ranking